Raptor Pharmaceuticals joins the Intercept rally

Add Raptor Pharmaceuticals (RPTP) to the list of stocks benefiting from the rally in liver disease plays sparked Thursday by ICPT.

The company — which is developing RP103 for NAFLD — saw its shares rise 6% yesterday, and early trading suggests today will be another positive session.

RPTP +7.5% premarket

See also: GALT, CNAT piggyback on ICPT NASH results

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs